

Hervé Ghesquière

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3894938/publications.pdf>

Version: 2024-02-01

51
papers

2,337
citations

331670

21
h-index

214800

47
g-index

52
all docs

52
docs citations

52
times ranked

3440
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. <i>Lancet, The</i> , 2011, 378, 1858-1867.	13.7	311
2	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNHO3-6B study): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 525-533.	10.7	257
3	Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. <i>Blood</i> , 2017, 129, 2471-2478.	1.4	200
4	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	4.1	180
5	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 2402-2411.	13.7	157
6	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3512.	1.6	144
7	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016, 18, 1297-1303.	1.2	135
8	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	1.6	93
9	Commercial <sc>anti-CD19 CAR</sc> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. <i>American Journal of Hematology</i> , 2020, 95, 1324-1333.	4.1	89
10	Efficacy of chemotherapy or chemo-anti-CD4 combination after failed anti-CD4 therapy for relapsed and refractory hodgkin lymphoma: A series from lisa centers. <i>American Journal of Hematology</i> , 2018, 93, 1042-1049.	4.1	87
11	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011, 96, 1136-1143.	3.5	84
12	Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. <i>Haematologica</i> , 2017, 102, 150-159.	3.5	61
13	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602.	1.6	59
14	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. <i>Blood</i> , 2012, 120, 2650-2657.	1.4	56
15	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	1.4	48
16	Early ¹⁸F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020, 61, 649-654.	5.0	39
17	Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogeneic stem cell transplantation. <i>European Journal of Cancer</i> , 2019, 115, 47-56.	2.8	33
18	First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. <i>American Journal of Hematology</i> , 2021, 96, 302-311.	4.1	32

#	ARTICLE	IF	CITATIONS
19	Performance of CT Compared with ¹⁸ F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. <i>Radiology</i> , 2020, 295, 651-661.	7.3	30
20	Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2856-2859.	1.4	25
21	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	1.6	24
22	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	3.2	16
23	Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. <i>European Journal of Cancer</i> , 2017, 72, 12-19.	2.8	14
24	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> <i>PVT1</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
25	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1074-1078.	2.5	13
26	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas. <i>American Journal of Surgical Pathology</i> , 2022, 46, 58-70.	3.7	12
27	Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1091-1101.	1.6	11
28	<i>FCGR3A</i> <i>2A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	1.7	9
29	A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the REal world dAta in LYmphoma and survival in adults (REALYSA) cohort. <i>BMC Public Health</i> , 2021, 21, 432.	2.9	9
30	Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. <i>Diagnostics</i> , 2022, 12, 417.	2.6	9
31	Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2022, 13, 841470.	4.8	9
32	Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. <i>British Journal of Haematology</i> , 2021, 193, 1110-1122.	2.5	8
33	Relapsed/Refractory International Prognostic Index (R ² PI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 599-605.	4.1	8
34	Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2812-2814.	1.3	8
35	<i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. <i>Leukemia and Lymphoma</i> , 2013, 54, 2571-2573.	1.3	7
36	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	3.7	7

#	ARTICLE	IF	CITATIONS
37	Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA). Blood, 2019, 134, 2832-2832.	1.4	5
38	Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Advances, 2022, 6, 6169-6179.	5.2	5
39	The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively. Cancers, 2021, 13, 2156.	3.7	4
40	Drug cost savings in phase III hematological oncology clinical trials in a university hospital. Hematological Oncology, 2020, 38, 576-583.	1.7	3
41	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematological Oncology, 2020, 38, 137-145.	1.7	3
42	BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres. British Journal of Haematology, 2021, 192, e94-e98.	2.5	3
43	Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication. Cancers, 2021, 13, 2272.	3.7	3
44	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. Blood, 2020, 136, 20-21.	1.4	3
45	Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. Cancers, 2022, 14, 660.	3.7	3
46	Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA). British Journal of Haematology, 2022, , .	2.5	3
47	PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma – Authors' reply. Lancet Oncology, The, 2019, 20, e190.	10.7	2
48	Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARE and MEDication) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2020, 15, e0243309.	2.5	2
49	A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study. Blood, 2019, 134, 4762-4762.	1.4	1
50	Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort. Cancers, 2019, 11, 1495.	3.7	0
51	Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. Leukemia and Lymphoma, 2022, 63, 599-607.	1.3	0